Phaseline

Companies › Sichuan Kelun-Biotech Biopharmaceutical

Sichuan Kelun-Biotech Biopharmaceutical: clinical trials, targets and expected readouts

17 active drug programs in 44 registered trials: 19 Phase 2, 15 Phase 1, 10 Phase 3; Oncology, Immunology, Respiratory; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sacituzumab Govitecan (SKB264)
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 3Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer …Nov 2026
Trastuzumab Botidotin (A166)
Receptor tyrosine-protein kinase erbB-2 binding agent; Tubulin inhibitor
ERBB2, TubulinPhase 3HER2-positive Breast Cancer; Her 2 Positive Breast CancerNov 2026
KL-A167–Phase 3Nasopharyngeal Carcinoma; Non-small Cell Lung Cancer; Small Cell Lung CancerDec 2026
Eribulin (SKB264)
Tubulin inhibitor
TubulinPhase 3Triple Negative Breast CancerJun 2027
SKB571
MET inhibitor
METPhase 2Non-small Lung Cancer; Gastrointestinal Tumors; Lung Cancer (Non-Small Cell); HNSCC …Dec 2026
SKB518
Unclear - code-named investigational drug
–Phase 2Lung Carcinoma; Advanced Gynecological Malignancies; Advanced Solid TumorsFeb 2027
SKB500–Phase 2Small Cell Lung Cancer; Esophageal Squamous Cell Carcinoma; Advanced Solid TumorsJul 2027
KL590586
RET inhibitor
RETPhase 1Advanced Solid TumorDec 2026
SKB445 for injection–Phase 1Advanced Solid TumorsDec 2026
SKB107
Lutetium-177 DOTA-conjugated radionuclide targeting bone metastases
–Phase 1Metastatic Solid TumorsOct 2027
SKB575 (HBM7575)–Phase 1Atopic Dermatitis; Asthma (Diagnosis)Dec 2027
SKB315 for injection
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 1Advanced Solid TumorsJun 2028
SKB565–Phase 1Advanced Solid TumorsMar 2029
SKB118 Injection–Phase 1Advanced Solid TumorsDec 2029
MK-6204 (SKB535) for Injection–Phase 1Advanced Solid TumorsDec 2029
SKB103 for injection–Phase 1Advanced Solid TumorsDec 2029
SKB105 for injection
Antibody-drug conjugate (ADC)
–Phase 1Advanced Solid TumorsDec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05870319Sacituzumab Govitecan (SKB264)Phase 3Non-small Cell Lung CancerOncologyJul 2024
NCT06428331SKB518Phase 1Advanced Solid TumorsOncologyJun 2026
NCT06448312Sacituzumab Govitecan (SKB264)Phase 3Non-Small Cell Lung CancerOncologyNov 2026
NCT06968585Trastuzumab Botidotin (A166)Phase 3HER2-positive Breast CancerOncologyNov 2026
NCT06725381SKB571Phase 1Solid MalignanciesOncologyDec 2026
NCT05351788KL-A167Phase 2Non-small Cell Lung CancerOncologyDec 2026
NCT06711900Sacituzumab Govitecan (SKB264)Phase 3Non-Small Cell Lung CancerOncologyDec 2026
NCT05351788Sacituzumab Govitecan (SKB264)Phase 2Non-small Cell Lung CancerOncologyDec 2026
NCT05631262Sacituzumab Govitecan (SKB264)Phase 2Selected Subjects With Advanced Solid TumorsOncologyDec 2026
NCT06826040SKB445 for injectionPhase 1Advanced Solid TumorsOncologyDec 2026
NCT06081959Sacituzumab Govitecan (SKB264)Phase 3Metastatic Breast CancerOncologyDec 2026
NCT05265091KL590586Phase 1Advanced Solid TumorOncologyDec 2026
NCT07019675SKB518Phase 2Lung CarcinomaOncologyFeb 2027
NCT06279364Sacituzumab Govitecan (SKB264)Phase 3Triple Negative Breast CancerOncologyApr 2027
NCT06670196Sacituzumab Govitecan (SKB264)Phase 3Non-Small Cell Lung CancerOncologyMay 2027
NCT05347134Eribulin (SKB264)Phase 3Triple Negative Breast CancerOncologyJun 2027
NCT07308106SKB571Phase 2Non-small Lung CancerOncologyJun 2027
NCT07071337Sacituzumab Govitecan (SKB264)Phase 3Metastatic Breast CancerOncologyJul 2027
NCT06736327SKB500Phase 1Advanced Solid TumorsOncologyJul 2027
NCT07564466SKB571Phase 2Gastrointestinal TumorsOncologyAug 2027
NCT07329322Sacituzumab Govitecan (SKB264)Phase 2Non-Small Cell Lung CancerOncologyAug 2027
NCT07299825Trastuzumab Botidotin (A166)Phase 2Her 2 Positive Breast CancerOncologySep 2027
NCT07087197SKB107Phase 1Metastatic Solid TumorsOncologyOct 2027
NCT05294172KL-A167Phase 3Nasopharyngeal CarcinomaOncologyDec 2027
NCT07448922SKB518Phase 2Advanced Gynecological MalignanciesOncologyDec 2027
NCT07488065SKB575 (HBM7575)Phase 1Atopic DermatitisImmunologyDec 2027
NCT07341100Sacituzumab Govitecan (SKB264)Phase 2Ovarian Epithelial CancerOncologyJan 2028
NCT07230405SKB571Phase 2Lung Cancer (Non-Small Cell)OncologyJan 2028
NCT07324629Sacituzumab Govitecan (SKB264)Phase 2Thymic CarcinomaOncologyApr 2028
NCT05367635SKB315 for injectionPhase 1Advanced Solid TumorsOncologyJun 2028
NCT07732023SKB575 (HBM7575)Phase 1Asthma (Diagnosis)RespiratoryJul 2028
NCT07697586Sacituzumab Govitecan (SKB264)Phase 2NSCLCOncologyAug 2028
NCT07697586Sacituzumab Govitecan (SKB264)Phase 2NSCLCOncologyAug 2028
NCT07668154SKB571Phase 2HNSCCOncologySep 2028
NCT07622186SKB571Phase 2Non-Small Cell Lung CancerOncologyDec 2028
NCT07296809SKB500Phase 2Small Cell Lung CancerOncologyDec 2028
NCT07700667SKB500Phase 2Esophageal Squamous Cell CarcinomaOncologyDec 2028
NCT07296809KL-A167Phase 2Small Cell Lung CancerOncologyDec 2028
NCT07545265SKB565Phase 1Advanced Solid TumorsOncologyMar 2029
NCT07586943SKB118 InjectionPhase 1Advanced Solid TumorsOncologyDec 2029
NCT07586943Sacituzumab Govitecan (SKB264)Phase 1Advanced Solid TumorsOncologyDec 2029
NCT07459998SKB103 for injectionPhase 1Advanced Solid TumorsOncologyDec 2029
NCT06726369MK-6204 (SKB535) for InjectionPhase 1Advanced Solid TumorsOncologyDec 2029
NCT07380386SKB105 for injectionPhase 1Advanced Solid TumorsOncologyDec 2029

Targets

Tubulin (2) CLDN18 (1) ERBB2 (1) MET (1) TACSTD2 (1) TOP1 (1) RET (1)

Companies with the same targets

AstraZeneca Roche Beijing Biotech Pfizer Merck & Co. (MSD) Daiichi Sankyo Astellas AbbVie Chia Tai Tianqing Pharmaceutical Group Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Companies built like this

Sichuan Baili Pharmaceutical Shanghai Hengrui Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical DualityBio Shenyang Sunshine Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.